5 results match your criteria: "Crohn's and Colitis Center of NJ[Affiliation]"
Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease.
Gastroenterol Res Pract
July 2015
Division of Gastroenterology and Hepatology, Crohn's and Colitis Center of NJ, Rutgers-Robert Wood Johnson Medical School, Clinical Academic Building, 125 Paterson Street, Suite 5100B, New Brunswick, NJ 08901-1962, USA.
Musculoskeletal manifestations are the most common extraintestinal manifestations in inflammatory bowel diseases. Some appendicular manifestations are independent of gut inflammation and are treated with standard anti-inflammatory strategies. On the other hand, axial involvement is linked to gut inflammatory activity; hence, there is a considerable amount of treatment overlap.
View Article and Find Full Text PDFMusculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms.
J Clin Gastroenterol
April 2014
*Department of Internal Medicine, St Peter's University Hospital, Drexel University College of Medicine ‡Department of Medicine, New York Medical College, Valhalla, NY †Rutgers-Robert Wood Johnson Medical School and University Hospital §Department of Medicine, Biochemistry and Molecular Biology, Rutgers-Robert Wood Johnson Medical School ∥Division of Gastroenterology and Hepatology, Rutgers-Robert Wood Johnson Medical School and University Hospital ¶Crohn's and Colitis Center of NJ, Rutgers-Robert Wood Johnson University Hospital, New Brunswick, NJ.
Inflammatory bowel diseases are chronic inflammatory disorders of multiple organ systems, primarily involving the gut, with chronic relapsing and remitting course. Musculoskeletal involvement is the most common extraintestinal manifestation. Distinct cell-mediated and humoral immunopathophysiological mechanisms have been identified underlying gut and joint inflammation in patients with inflammatory bowel disease and arthritis.
View Article and Find Full Text PDFAntibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis.
Am J Gastroenterol
December 2009
Department of Medicine and Physiology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Crohn's and Colitis Center of NJ, New Brunswick, New Jersey 08903, USA.
Objectives: Tropomyosins (TMs) are cytoskeletal microfilament proteins present in all eukaryotic cells. Human TM isoform 5 (hTM5) is the predominant isoform in colonic epithelial cells. Antibodies against hTM5 are found both in the sera and in the mucosa of patients with ulcerative colitis (UC) but not Crohn's disease (CD).
View Article and Find Full Text PDFAutoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis.
Cell Immunol
November 2006
Crohn's and Colitis Center of NJ, Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place, MEB 478, New Brunswick, NJ 08903, USA.
Introduction: Patients with ulcerative colitis (UC) have IgG1 antibodies in serum and colon against human tropomyosin isoform 5 (hTM5), a cytoskeletal microfilament protein found intracellularly and on the surface of colonic epithelial cells (EC). These antibodies may be pathogenic in UC.
Methods: Sera from patients with UC (n=110) or Crohn's disease (CD) (n=50) and from healthy individuals (Hl) (n=30) were preincubated with recombinant hTM5 or bovine serum albumin (BSA), then cultured for 4h with (51)Cr-labelled colonic adenocarcinoma cells (LS180).
The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
J Clin Gastroenterol
January 2005
Crohn's and Colitis Center of NJ, Division of Gastroenterology and Hepatology, Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 0893, USA.
Goals: To report the 10-year experience of a single center in treating patients with refractory inflammatory bowel disease (IBD) with relatively lower dose of 6-mercaptopurine (6-MP).
Study: The charts of 285 patients with IBD (Crohn's disease 160 and ulcerative colitis 125) receiving 6-MP were reviewed. Clinical response, subsequent breakthrough while taking 6-MP, and relapse rates when 6-MP was discontinued and side effects were assessed.